DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Cut to $13.00 by Analysts at UBS Group

DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) had its price objective lowered by analysts at UBS Group from $17.00 to $13.00 in a report released on Monday, Benzinga reports. The firm currently has a “buy” rating on the medical instruments supplier’s stock. UBS Group‘s target price suggests a potential upside of 43.41% from the stock’s current price.

XRAY has been the topic of several other research reports. Barrington Research cut their price target on DENTSPLY SIRONA from $15.00 to $13.00 and set an “outperform” rating on the stock in a research note on Monday, October 26th. Barclays lifted their price objective on DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a research report on Monday, August 24th. Bank of America reissued a “buy” rating on shares of DENTSPLY SIRONA in a report on Friday, November 6th. Leerink Partners cut their target price on shares of DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating on the stock in a research report on Wednesday, October 14th. Finally, Piper Sandler cut their target price on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Friday, October 9th. Three equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $12.08.

Check Out Our Latest Stock Analysis on DENTSPLY SIRONA

DENTSPLY SIRONA Trading Down 1.0%

NASDAQ:XRAY traded down $0.10 during trading hours on Monday, hitting $9.06. 867,408 shares of the stock were exchanged, compared to its average volume of 4,928,026. The company’s 50 day moving average is $9.43 and its two-hundred day moving average is $11.20. DENTSPLY SIRONA has a twelve month low of $8.14 and a twelve month high of $14.76. The company has a quick ratio of 1.04, a current ratio of 1.63 and a debt-to-equity ratio of 1.47. The company has a market capitalization of $1.80 billion, a P/E ratio of -14.60, a price-to-earnings-growth ratio of 1.34 and a beta of 0.87.

DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.02). The firm had revenue of $836.00 million during the quarter, compared to the consensus estimate of $861.68 million. DENTSPLY SIRONA had a negative net margin of 3.38% and a positive return on equity of 20.21%. The firm’s quarterly revenue was down 7.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.37 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.200-1.300 EPS. On average, sell-side analysts anticipate that DENTSPLY SIRONA will post 1.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DENTSPLY SIRONA

Institutional investors have recently modified their holdings of the stock. Paradigm Capital Management Inc. NY bought a new stake in shares of DENTSPLY SIRONA in the 2nd quarter valued at about $39,775,000. BlackRock Inc. acquired a new stake in shares of DENTSPLY SIRONA in the 2nd quarter valued at approximately $283,405,000. The Manufacturers Life Insurance Company acquired a new stake in shares of DENTSPLY SIRONA in the 2nd quarter valued at approximately $1,956,000. Bank of New York Mellon Corp bought a new position in DENTSPLY SIRONA during the 2nd quarter worth approximately $16,408,000. Finally, Edmond DE Rothschild Holding S.A. bought a new position in DENTSPLY SIRONA during the 2nd quarter worth approximately $47,780,000. 95.70% of the stock is currently owned by institutional investors and hedge funds.

DENTSPLY SIRONA Company Profile

(Get Free Report)

DENTSPLY SIRONA Inc. develops, manufactures and markets products and technologies for dental professionals. Its portfolio includes dental equipment and imaging systems, digital dentistry and CAD/CAM solutions, dental implants, endodontic and restorative products, and supplies used in preventive care. The company serves dental practices, laboratories and other customers around the world. Its products support a range of clinical activities, including diagnosis, treatment planning, restorative dentistry and oral hygiene.

Further Reading

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.